1 February, 2026

EU Implementing Regulation (EU) 2025/1466

Insights Hub

Evolving pharmacovigilance requirements are creating increasing regulatory and operational complexity for Marketing Authorisation Holders (MAHs) seeking to maintain compliance in a more transparent, data-driven EU environment.

With the adoption of Commission Implementing Regulation (EU) 2025/1466, regulatory expectations are rising across QPPV oversight, signal management, PSURs, PASS governance, vendor oversight, and risk-based audits. The focus is shifting from procedural compliance to continuous oversight, traceability, and demonstrable control across outsourced and internal pharmacovigilance activities.

Download our latest guide to explore how our integrated services, expert teams, and innovative technology suite support safety and quality across the full product lifecycle — from clinical development to post-marketing surveillance.

Read our guide to explore more about:

How Regulation (EU) 2025/1466 reshapes EU pharmacovigilance expectations and amends Regulation (EU) No 520/2012
What the new requirements mean for QPPV oversight, governance models, and organisational transparency
How signal management, PSURs, PASS, and ICSR standards are changing in practice
How to operationalise risk-based oversight, vendor governance, and audit strategies while remaining inspection-ready

Please submit form to access content.

"*" indicates required fields

Facebook

This field is for validation purposes and should be left unchanged.

First Name*

Last Name*

Job Title

Industry*

Company*

Business Email*

Phone

Country*

State*

By submitting this form, you consent to your personal data being processed in alignment with our privacy policy. Your personal data will be processed for purpose of facilitating your request and may be used for sending you additional marketing and business development-related information about PrimeVigilance, its affiliates and our services. You can withdraw your consent at any time at marketing@ergomedgroup.com, and your personal data will be erased. For more information about our privacy policy and your privacy rights, please visit our website’s data policy section.

Ergomed Group Announces Board Chair Transition

Prudentia a Gold sponsor at Veeva R&D and Quality Summit 2026

Our Company

End-to-end services for high-quality safety and pharmacovigilance operations

Technology-driven solutions integrated into the pharmacovigilance landscape

Product expertise which enables efficiencies in PV operations

Insights Hub

Trending Topics, Case Studies, Articles

Latest Case Study

Webinars

Latest Webinar

News and Events

EU Implementing Regulation (EU) 2025/1466

Evolving pharmacovigilance requirements are creating increasing regulatory and operational complexity for Marketing Authorisation Holders (MAHs) seeking to maintain compliance in a more transparent, data-driven EU environment.

Discover how we can help you

Our Company

End-to-end services for high-quality safety and pharmacovigilance operations

Technology-driven solutions integrated into the pharmacovigilance landscape

Product expertise which enables efficiencies in PV operations

Insights Hub

Trending Topics, Case Studies, Articles

Latest Case Study

Webinars

Latest Webinar

News and Events

Ergomed Group Announces Board Chair Transition

Prudentia a Gold sponsor at Veeva R&D and Quality Summit 2026

EU Implementing Regulation (EU) 2025/1466

Evolving pharmacovigilance requirements are creating increasing regulatory and operational complexity for Marketing Authorisation Holders (MAHs) seeking to maintain compliance in a more transparent, data-driven EU environment.

Related Resources

Blog

EU Pharmacovigilance Regulation 2025/1466: Key Changes and Impact for MAHs

Discover how we can help you